12. Earnings/loss (–) per share
|
Year ended 31 December |
|
|---|---|---|
|
2023 |
2022 |
Net profit/loss (-) attributable to owners of the parent (thousands of €) |
211,697 |
(217,991) |
|
|
|
Number of shares (thousands) |
|
|
Weighted average number of shares for the purpose of basic earnings / loss (-) per share |
65,884 |
65,699 |
|
|
|
Basic earnings/loss (-) per share (€) |
3.21 |
(3.32) |
|
|
|
Net profit/loss (-) attributable to owners of the parent (thousands of €) |
211,697 |
(217,991) |
|
|
|
Number of shares (thousands) |
|
|
Weighted average number of shares for the purpose of diluted earnings / loss (-) per share |
65,884 |
65,699 |
Number of dilutive potential ordinary shares |
49 |
- |
|
|
|
Diluted earnings/loss (-) per share (€) |
3.21 |
(3.32) |
As we reported a net loss in 2022, the outstanding subscription rights (specified in note 31) have an anti-dilutive effect rather than a dilutive effect. Consequently, basic and diluted loss per share is the same for 2022.
Reference is also made to note 2 where an explanation is provided about the terms and conditions of the outstanding Gilead Warrant B that can, potentially, be exercised by Gilead and lead to a dilutive effect. Due to the exercise price mechanism of the Gilead Warrant B, this warrant was out-of-the-money for all years presented.